US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Shattuck Labs Inc (STTK)
Shattuck Labs Inc (STTK) ニュース

Shattuck Labs Inc (STTK)

6.44

0.53

(8.97%)

終了 6月29日 5:00AM

6.48

0.04

(0.62%)

取引時間後: 8:20AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Shattuck Labs, Inc. Announces Proposed Public Offering

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the...

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:...

Shattuck Labs Announces Phase 1 Results for SL-325

Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug...

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

TrendTrade2016

TrendTrade2016 6月前

STTK...HERE WE GO

TrendTrade2016

TrendTrade2016 6月前

STTK...WEEKLY BIO BEAST

glenn1919

glenn1919 7月前

STTK........................................https://stockcharts.com/sc3/ui/?s=STTK&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 10月前

STTK.................................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 10月前

STTK.................................................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

swingforthe fence

swingforthe fence 11月前

Lets Go Get It STTK $$$$$

glenn1919

glenn1919 11月前

sttk..........................................................P/M

TrendTrade2016

TrendTrade2016 1年前

STTK HERE COMES 2.00

TrendTrade2016

TrendTrade2016 1年前

STTK...2.40 MAGNET.....NO...DO WE DARE

TrendTrade2016

TrendTrade2016 1年前

STTK...MINI MONSTER GETTING LOTS OF LOVE

TrendTrade2016

TrendTrade2016 1年前

STTK...HERE WE GO

TrendTrade2016

TrendTrade2016 1年前

STTK BUILDING MOMO

PonkenPlonken

PonkenPlonken 1年前

(STTK uses too) CD47
https://med.stanford.edu/news/all-news/2017/11/second-dont-eat-me-signal-found-on-cancer-cells.html

https://www.gilead.com/news/news-details/2020/gilead-to-acquire-forty-seven-for-49-billion

TrendTrade2016

TrendTrade2016 1年前

HAVE NO CLUE WHAT THAT MEANS

PonkenPlonken

PonkenPlonken 1年前

I used to love this - always love me some dont eat me

TrendTrade2016

TrendTrade2016 1年前

STTK LOW VOLUME MOVE....SO DILUTION OFF THE TABLE

TrendTrade2016

TrendTrade2016 2年前

STTK COMING OFF BOTTOM

glenn1919

glenn1919 2年前

STTK............................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

PonkenPlonken

PonkenPlonken 2年前

absolutely revolutionary data in HR MDS... compare to SOC!!! HMAs show a ORR 30%, CR 10-20%
(also beats venetoclax + HMA in TP53m AML)

Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –

– Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment

Monksdream

Monksdream 2年前

STTK new 52 week high

Monksdream

Monksdream 2年前

STTK new 52 week high

Monksdream

Monksdream 2年前

STTK new 52 week low

tbonaces80

tbonaces80 3年前

Takeda gonna tender on next trial fast track

tbonaces80

tbonaces80 3年前

load it-going to 10+

subslover

subslover 3年前

No fooling? So you say a 1.75% profit for a two-hour trade is a bad trade?

tbonaces80

tbonaces80 3年前

subslover

subslover 3年前

Ok. I got out of this POS this morning at $5.00, got lucky is all

TheFinalCD

TheFinalCD 3年前

@ 4.29 I was just looking for a move under $4 and it did

small gain, but I didnt know how many borrows I could get if it went against me

sometimes I go short, and get upside down and cant average up, because broker all of a sudden has NO available shares to short= your stuck

so thats why I dont short much

subslover

subslover 3年前

What price did you short?tia

TheFinalCD

TheFinalCD 3年前

I shorted it... Its just Phase 1

AI bot hyper extended the POP

I used to chase these Pase 1 rallys, lost lots of money doing so

some of my biggest losses ever

Phase 1 Gap & Traps

subslover

subslover 3年前

Did you see this open? $7.28! then immediately dropped down to $2.50 omg. I'm in at $3.00 just hoping for the best. Worth a shot

TheFinalCD

TheFinalCD 3年前

$STTK KEEP THIS ON WATCH! pic.twitter.com/6owPN2LcXn— Tiger Line Trading (@TigerLineTrades) December 13, 2023

subslover

subslover 3年前

$TSOI's new Introducing the ALScell™, also known as the JadiCell™ – Now, these ALScells are not your run-of-the-mill mesenchymal stem cells; they're basically the overachievers of the cellular world. These ALScells have it all – enhanced growth factor production, like they've been hitting the gym and drinking protein shakes on a regular basis. They can secrete exosomes , outshining their stem cell peers who are still trying to figure out how to tie their cellular shoelaces.

But wait, there's more! These ALScells are not just content with being academically gifted; they've got some serious street smarts too. Superior angiogenic and neurogenic abilities mean they're like the cool kids who not only excel in science class but also throw legendary parties in the cellular neighborhood.

And guess what? Exosomes are not just a fancy word; they're the VIP pass to the cure of many cancers. It's like the ALScells are hosting the party, and exosomes are the invitations that cancer cells can't resist.

So, say hello to the ALScell™ – the cellular superhero ready to save the day, one enhanced growth factor at a time, and unlocking cures like a boss!
Bullish
BULLISH

Awl416

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pati

Monksdream

Monksdream 3年前

Hamborner REIT AG NA ON

Dermasalve Sciences

TPG Pace Beneficial II

Xtrac Eu Def T 1cc

Leverage Shares Public

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。